TRIM33 and cancer: The current study identified VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ (CCL2, IL-6, and IFN-γ after Bonferroni correction) as additional plasma biomarkers reflecting cancer presence, in addition to anti-TIF1-γ antibody, among anti-TIF1-γ antibody-positive DM patients.